Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FDL169 in Cystic Fibrosis
NCT03093714Phase 1Completed
- Sponsor
- Flatley Discovery Lab
- Start
- Aug 2017
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, randomised, double-blind trial of FDL169 in cystic fibrosis (CF) (4 arms), sponsored by Flatley Discovery Lab. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 28 days. Started Aug 2017; status: completed.
02
Drugs
FDL169
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT03093714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03093714.